DRUG
Maridebart Cafraglutide
Maridebart cafraglutide will be administered via subcutaneous (SC) injection.
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Status
Recruiting
Phase
Phase 3
Enrollment
300
Locations
44
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
May 8, 2026
Study start
May 11, 2026
Primary completion
Jan 3, 2028
Study completion
Feb 28, 2028
Results posted
Not reported
Registry updated
Jul 23, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight at Week 68
Time frame · Week 68
Secondary outcomes
Percent Change in Body Weight Prior to the Start of Weekly GLP-1RA at Week 68
Time frame · Week 68
Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
Time frame · Week 68
Percent Maintenance of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
Time frame · Week 68
Plasma Concentration of Maridebart Cafraglutide at Week 68
Time frame · Week 68
Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
Time frame · Up to 84 weeks
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Body Mass Index (BMI) ≥ 25 at screening. * Weight loss of ≥ 10% on weekly GLP-1 RA. * Stable body weight. * Stable dose of GLP-1RA. * Stable gastrointestinal (GI) tolerability. * Contraception for females. * Willingness to follow trial procedures for the duration of the trial. Exclusion Criteria: * Obesity induced by other endocrine disorders (ex: Cushing's syndrome). * Previous or planned surgical, endoscopic or device-based treatment for obesity. * History of malignancy. * Type 1/Type 2 diabetes mellitus (DM). * Family or personal history of medullary thyroid cancer. * Previous participation in a Maridebart Cafraglutide trial.
Study locations
44 registered sites.
Puerto Rico · United States. Showing up to 24 locations stored in the fast local snapshot.
Cahaba Research, Inc.
Pelham, Alabama, United States
Arizona Clinical Trials
Chandler, Arizona, United States
Epic Medical Research - Sun City
Sun City, Arizona, United States
Desert Oasis Healthcare Medical Group
Palm Springs, California, United States
Inland Empire Liver Foundation
Rialto, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Apex Clinical Research
San Diego, California, United States
Southern California Clinical Research
Santa Ana, California, United States
University of Florida Department of Medicine
Gainesville, Florida, United States
Aga Clinical Trials
Hialeah, Florida, United States
South Florida Clinical Research
Margate, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Research Institute of South Florida
Miami, Florida, United States
Clinical Neuroscience Solutions
Orlando, Florida, United States
Florida Institute for Clinical Research
Orlando, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Charter Research - The Villages
The Villages, Florida, United States
Nsc Research
Johns Creek, Georgia, United States
Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group
Union City, Georgia, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Solaris Clinical Research
Meridian, Idaho, United States
Endeavor Health
Skokie, Illinois, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division
Troy, Michigan, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Maridebart cafraglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center · Opioid Use Disorder · Opioid Abuse and Addiction
Phase 2
Recruiting
200
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.